The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, particularly for tumors that evade the immune system by expressing proteins such as programmed death-ligand 1 (PD-L1) and inhibiting T cell activity [1]. However, a significant subset of patients does not respond to ICIs due to intrinsic resistance mechanisms including the tumor microenvironment (TME) [2, 3].

Among the various molecular players in cancer progression, fibroblast growth factor receptor 1 (FGFR1) has emerged as a critical target for therapeutic intervention [4]. FGFR1 belongs to the FGFR family of receptor tyrosine kinases, which are involved in numerous biological processes. Dysregulation of FGFR1 has been observed in several cancers, including lung cancer, breast cancer, renal cell carcinoma (RCC), and head and neck tumors, where its overexpression is often associated with poor prognosis [5–8]. Furthermore, FGFR1 has been implicated in promoting resistance to ICIs by modulating the immune microenvironment and enabling immune evasion [9].

Given the pivotal role of FGFR1 in tumor biology and immune evasion, targeting FGFR1 represents a promising approach to enhance the efficacy of immunotherapy. This perspective will explore the biological significance of FGFR1 in cancer progression, the mechanisms by which it contributes to immunotherapy resistance, and the emerging evidence supporting FGFR1-targeting therapies in combination with ICIs.

FGFR1 has been explored as a therapeutic target in oncology for over a decade. Multiple strategies have emerged to block FGFR1 activity, including the use of tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (Table 2). Various TKIs targeting FGFR1 have undergone clinical evaluation in patients with FGFR1-amplified malignancies. Despite some promise, these agents often encounter hurdles such as acquired resistance and unintended interactions that undermine their long-term effectiveness. Examples of broad-spectrum FGFR inhibitors include BGJ398, AZD4547, and JNJ-42756493, all of which act on FGFR1–3 [37–39]. Though preclinical outcomes were encouraging, translation into clinical benefit has been limited. For instance, in a phase I study, only 11% of FGFR1-amplified NSCLC patients exhibited partial responses to BGJ398.

Conversely, treatments have shown greater promise in relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. The efficacy of pemigatinib was assessed in the multicenter FIGHT-203 trial, which included 28 such patients [40], with 78% achieving durable complete responses—supporting subsequent FDA approval [41]. Another approach gaining traction is the development of more selective FGFR inhibitors. Alofanib, targeting FGFR2 specifically, has demonstrated strong activity in both preclinical and early-phase clinical studies [42, 43]. Similarly, futibatinib, a selective pan-FGFR blocker, is being studied in FGFR1-positive cohorts [44].

Monoclonal antibodies that bind the extracellular portion of FGFR1 represent a more targeted modality. One example, OM-RCA-01, is a humanized antibody designed to inhibit FGFR1 activation and downstream signaling cascades. In our investigation, we evaluated the capacity of OM-RCA-01 to suppress tumor cell proliferation in vitro and impede tumor progression in vivo. We further hypothesized that combining this antibody with ICIs could improve treatment responses, particularly by addressing resistance mechanisms tied to the TME.

In vitro data showed that OM-RCA-01 significantly diminished FGF-driven proliferation in lung and renal carcinoma cell lines [45, 46], accompanied by a dose-dependent reduction in FGFR1 phosphorylation. In melanoma cells, where baseline FGFR1 phosphorylation was low, the antibody exhibited limited antiproliferative effects. Other studies have similarly linked FGFR1 phosphorylation to cellular proliferation [47–49], reinforcing the notion that extracellular receptor blockade impairs intracellular kinase signaling. Future work should examine downstream kinase phosphorylation in response to OM-RCA-01. Prior findings from other FGFR-targeted agents indicate that extracellular domain inhibition can also disrupt intracellular signaling proteins [50, 51].

These findings were corroborated in vivo using a lung cancer xenograft model [45]. Mice treated with non-specific IgG developed rapidly growing tumors that reached approximately 2,000 mm³, whereas OM-RCA-01 monotherapy substantially curtailed tumor expansion—achieving a twofold size reduction by day 31. This likely resulted from both direct tumor suppression and reduced angiogenesis. Supporting this, OM-RCA-01 previously outperformed bevacizumab in a Matrigel-based angiogenesis assay [46].

The next phase of our study focused on exploring the potential of combining immunotherapy with anti-FGFR1 targeting. Immune checkpoint blockade has revolutionized cancer treatment, yet resistance remains a significant clinical obstacle. For instance, only about 30% of metastatic lung cancer patients and 48% of kidney cancer patients reach a five-year survival benchmark following checkpoint inhibitor combinations such as pembrolizumab or nivolumab with ipilimumab [52, 53].

This emphasizes the need for novel strategies to enhance immunotherapy durability and counteract resistance. While early-phase investigations have tested FGFR TKIs alongside PD-1 inhibitors [54, 55], no completed studies have evaluated monoclonal FGFR1 antibody combinations. This represents a promising area for further exploration. One current trial, FORTITUDE-102, is assessing the combination of anti-FGFR2 antibody bemarituzumab with nivolumab and chemotherapy in metastatic gastric cancer patients [56].

Our in vitro experiments confirmed that nivolumab augments T cell activation, consistent with prior reports showing elevated interferon-gamma (IFNγ) and IL-2 levels in co-cultures treated with nivolumab or nivolumab/ipilimumab [57, 58]. Notably, adding OM-RCA-01 further increased IFNγ release by 33% and IL-2 by 74%. The underlying mechanisms are still unclear. Previous work from our lab found FGFR expression on human lymphocytes [12], implying a possible direct immunomodulatory effect. Although a nonspecific immunoglobulin response cannot be ruled out, OM-RCA-01 alone did not elicit significant cytokine release, and preclinical toxicology studies did not identify any notable immune stimulation.

In vivo, the OM-RCA-01 plus checkpoint inhibitor combination enhanced therapeutic efficacy in a patient-derived xenograft (PDX) lung cancer model overexpressing FGFR1. While pembrolizumab monotherapy is standard for metastatic NSCLC with ≥ 50% PD-L1 expression, the interplay between PD-L1 and FGFR1 co-expression remains underexplored. A phase 2 study (NIVOFGFR2) in gastric cancer showed diminished nivolumab efficacy when tumors co-expressed PD-L1 and FGFR2 [59]. Our PDX model featured high levels of both FGFR1 and PD-L1, and tumor growth in the control group was aggressive. By contrast, dual treatment with OM-RCA-01 and pembrolizumab achieved a twofold tumor volume reduction compared to checkpoint inhibitor monotherapy. The absence of a treatment arm using OM-RCA-01 alone is a limitation, but comparative results suggest that its therapeutic impact is magnified when combined with pembrolizumab.

As discussed earlier, TME is pivotal in ICI resistance, with cancer-associated fibroblasts (CAFs) playing a central role [60]. CAFs support metastasis through extracellular matrix remodeling, growth factor production, and modulation of angiogenesis, tumor rigidity, and drug response [61]. Various approaches are under development to neutralize CAF-mediated resistance, including altering their composition or activity. In our model, tumor progression accelerated in the presence of CAFs, with nivolumab efficacy markedly reduced [45]. However, the introduction of OM-RCA-01 upon onset of resistance delayed tumor expansion. Tumors in the CAF-positive cohort did not exceed 2,000 mm³, in contrast to controls treated with non-specific IgG. Furthermore, cytokine levels such as IFNγ and IL-2 surged again with OM-RCA-01 therapy. Although these data are not sufficient to draw definitive conclusions about OM-RCA-01’s role in modulating the TME, the results suggest potential direct and indirect antitumor effects. Importantly, OM-RCA-01 was well tolerated, showing no adverse events at or above therapeutic dosages. Pharmacokinetic profiles indicated prolonged clearance and sustained plasma levels, pointing to favorable bioavailability and drug persistence.

Despite the first promising data on FGFR1-targeted therapies, several challenges must be addressed before these therapies can be fully integrated into clinical practice. One of the primary challenges is the development of resistance to FGFR1 inhibitors. Similar to other targeted therapies, cancer cells may develop mutations in the FGFR1 pathway or activate alternative signaling pathways to bypass FGFR1 inhibition, ultimately leading to therapeutic resistance. Understanding these mechanisms is critical for developing strategies to sustain long-term efficacy.

Another challenge lies in the complexity of the TME. While FGFR1 inhibition can reduce immune suppression and enhance ICI efficacy, the TME remains a dynamic and heterogeneous environment. Other immunosuppressive factors, such as Tregs, MDSCs, and immunosuppressive cytokines like TGF-β, may still limit the effectiveness of combination therapies. Therefore, therapeutic strategies that target not only FGFR1 but also additional components of the TME may be necessary to achieve optimal outcomes.

To overcome these challenges, several emerging strategies are being explored. One approach involves developing next-generation FGFR inhibitors with enhanced specificity and reduced toxicity. These novel agents aim to minimize off-target effects and mitigate resistance mechanisms, making them better suited for long-term combination with ICIs. Another area of active research is the identification of predictive biomarkers to guide patient selection as FGFR1 amplification, FGFR1 mutations, and FGFR1 expression levels are being studied to help identify patients most likely to benefit from FGFR1-targeted therapies as single agents or combined with ICIs. The development of reliable biomarkers will be critical for personalizing treatment approaches and improving clinical outcomes. Furthermore, researchers are exploring the use of circulating tumor DNA and other liquid biopsy techniques to dynamically monitor FGFR1 mutations and treatment response over time.

An emerging strategy could be exploring the efficacy of chimeric antigen receptor (CAR) T cell therapy targeting FGFR1. Such approach could further enhance antitumor efficacy by targeting FGFR1-overexpressing tumor cells [62].

Notably, FGFR TKIs augmented the antitumor effect of FGFR1-reactive T cells against human head and neck cancers [63]. These results suggest that FGFR TKIs are potential immune adjuvants for T cell-based immunotherapy. Combination therapy with TKIs and cancer vaccines or ICI could be a novel and potent immunotherapeutic approach to treat aggressive cancers with FGFR expression.

Finally, a new concept is to use the FGFR as a substrate for the attachment of the antibody-drug conjugate to the cancer cell. So far, attempts to create such conjugates have not been successful due to poor tolerability, however, further developments are underway [64, 65].

Large-scale clinical trials are needed to confirm the efficacy and safety of FGFR1-targeted therapies alone or in combination with ICIs. While early-phase trials have shown promising results, larger, randomized studies are required to validate these findings across different cancer types and patient populations. These trials should also explore variations in treatment protocols, such as different dosing regimens and the sequencing of FGFR1 inhibitors and ICIs. The results of these studies will provide crucial insights into how best to implement FGFR1-targeted therapies in clinical practice.